Solid Biosciences Inc.
SLDB evidence brief
What we can confirm
- BioSniper Score:
- 7.2 / 10
- Market Cap:
- $972.5M
- Lead Asset:
- SGT-601 (Phase 3)
What it means
What to watch
Prepared research question
What matters most for SLDB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SLDB
Solid Biosciences Inc. (SLDB) is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, with a lead Duchenne muscular dystrophy gene therapy program in Phase 3 and a funded cash runway into mid-2028.
Key risk: Competition from approved DMD therapy
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$972.5M
Cash Runway
—
Lead Asset
SGT-601 (Phase 3)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Solid Biosciences Inc..
Solid Biosciences Inc. (SLDB) is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, with a lead Duchenne muscular dystrophy gene therapy program in Phase 3 and a funded cash runway into mid-2028.
- Cash & equivalents of $159.4M and shareholders' equity of $374.1M as of 2026-06-30 [sec].
- Lead candidate SGT-003 (Duchenne muscular dystrophy) is in Phase 3, with 33 participants dosed in the Phase 1/2 INSPIRE DUCHENNE trial as of January 9, 2026 [news · 2026-01-14].
- First participant dosed in Phase 1b FALCON trial for SGT-212 (Friedreich's Ataxia) in January 2026, with initial data expected H2 2026 [news · 2026-01-12].
- Proprietary next-generation capsid AAV-SLB101 has been licensed to over 25 academic and corporate partners [news · 2025-08-13].
- Cash runway extends into mid-2028, providing funding for Duchenne gene therapy programs [news · 2026-09-25].
What works
- SGT-003 has been generally well tolerated using a steroid-only prophylactic immunomodulation regimen, with cardiac safety monitoring showing reduction in cardiac troponin levels [news · 2025-11-04].
- The company has a funded cash runway into mid-2028, supporting ongoing and planned clinical trials [news · 2026-09-25].
- AAV-SLB101 capsid has generated over 25 licensing agreements with academic labs, institutions, and corporations, indicating broad external validation [news · 2025-08-13].
- SGT-003 has received Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA [pipeline].
What to weigh
- SGT-003 faces competition from ELEVIDYS, an approved Duchenne gene therapy [pipeline].
- SGT-212 (Friedreich's Ataxia) is in early Phase 1b testing, with initial data not expected until H2 2026, so clinical proof-of-concept is still pending [news · 2026-01-12].
- Cash position declined from $306.9M at Q1 2025 to $159.4M as of mid-2026, reflecting significant spending on R&D and clinical operations [news · 2025-05-16] [sec].
- The company has no approved products and is entirely dependent on clinical trial outcomes and regulatory approvals for future revenue.
From the filings
Quoted directly from source documents.
SGT-003 Phase 3 status and dosing count
“Dosed 33 participants in the Phase 1/2 INSPIRE DUCHENNE clinical trial as of January 9, 2026”
News · January 14, 2026
First participant dosed in SGT-212 Phase 1b FALCON trial
“the first participant has been dosed in FALCON, the Company’s Phase 1b, first-in-human clinical”
News · January 12, 2026
Cash runway into mid-2028
“Solid Biosciences has a funded cash runway into mid-2028 for Duchenne gene therapy”
News · September 25, 2026
Catalyst timeline
- 2017-12-06 · Phase 2 Start for SGT-001 (DMD) — A Phase 1/2 study of SGT-001 in Duchenne muscular dystrophy began in December 2017.
- 2024-05-06 · Phase 2 Start for SGT-003 (DMD) — The INSPIRE DUCHENNE Phase 1/2 trial for SGT-003 started in May 2024.
- 2025-10-22 · Phase 1 Start for SGT-212 (FA) — The FALCON Phase 1b trial for SGT-212 in Friedreich's Ataxia began in October 2025.
Risks & what to watch (4)›
Key risks
- Competition from approved DMD therapy — SGT-003 competes with ELEVIDYS, an approved Duchenne gene therapy, which may limit market share [pipeline].
- Early-stage pipeline uncertainty — SGT-212 and SGT-501 are in Phase 1b; clinical data and regulatory outcomes are years away [news · 2026-01-12].
- Cash burn rate — Cash declined from $306.9M (Q1 2025) to $159.4M (mid-2026), indicating high spending without revenue [news · 2025-05-16] [sec].
- No approved products — Company has no marketed products; all future revenue depends on clinical and regulatory success [pipeline].
What to watch
- FDA regulatory pathway discussions for SGT-003, expected in H1 2026 [news · 2025-11-04].
- Initial data from the Phase 1b FALCON trial for SGT-212, expected H2 2026 [news · 2026-01-12].
- Patient dosing in the Phase 3 IMPACT DUCHENNE trial, expected Q1 2026 [news · 2026-01-14].
- Additional data from the Phase 1/2 INSPIRE DUCHENNE trial anticipated mid-2026 [news · 2026-01-14].
Sources: Catalysts · News · Pipeline · Generated October 4, 2026 · How we verify sources →
Run Solid Biosciences Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Solid Biosciences Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.12 · 0% dilution
Lead: Phase 3
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
142
Total value held
$716.7M
| Holder | Shares | Value |
|---|---|---|
| perceptive advisors llc | 11,906,646 | $85.7M |
| bain capital life sciences investors, llc | 9,808,819 | $70.6M |
| ra capital management, l.p. | 9,339,978 | $67.2M |
| siren, l.l.c. | 7,690,405 | $55.4M |
| vestal point capital, lp | 5,000,000 | $36.0M |
| blackrock, inc. | 4,958,354 | $35.7M |
| janus henderson group plc | 4,010,695 | $28.9M |
| fmr llc | 3,606,404 | $26.0M |
| deep track capital, lp | 3,565,062 | $25.7M |
| armistice capital, llc | 3,200,000 | $23.0M |
Showing top 10 of 142 institutional holders of Solid Biosciences Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 11.7%
- Days to cover
- 5.8
- Shares short
- 10,049,470
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SLDB short interestGovernance
Frequently asked questions
What is the AI investment thesis for Solid Biosciences Inc.?
Solid Biosciences Inc. (SLDB) is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, with a lead Duchenne muscular dystrophy gene therapy program in Phase 3 and a funded cash runway into mid-2028.
What is Solid Biosciences Inc.'s lead drug candidate?
Solid Biosciences Inc.'s most advanced tracked candidate is SGT-601 (Phase 3) for TNNT2-mediated dilated cardiomyopathy.
Who is the CEO of Solid Biosciences Inc.?
Mr. Alexander G. Cumbo is the chief executive officer of Solid Biosciences Inc. (SLDB).
Where is Solid Biosciences Inc. headquartered?
Solid Biosciences Inc. (SLDB) is headquartered in Charlestown, MA, United States.
What therapeutic areas does Solid Biosciences Inc. focus on?
Solid Biosciences Inc. develops therapies across Rare Disease, Neurology, Cardiovascular.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.